| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Others (not specifically classified into major target families). Rhodojaponin V acts on voltage-gated sodium channels, disrupting nerve signal transmission. It also exhibits anti-inflammatory activity, potentially through inhibition of nitric oxide production in macrophages. The compound is studied as a natural lead compound for botanical pesticide development and neuropharmacological research.
|
|---|---|
| ln Vitro |
Rhodojaponin V exhibits anti-inflammatory activity in mouse RAW264.7 macrophages by inhibiting LPS-induced nitric oxide production. The compound shows an IC50 of approximately 40,000 nM (40 uM) in this assay, indicating a moderate to weak inhibitory effect. No other specific in vitro activity data is reported.
|
| ln Vivo |
No specific in vivo activity data is available for Rhodojaponin V. Based on its insecticidal properties, it may have been studied in insect models for its neurotoxic effects. Its anti-inflammatory activity suggests potential for in vivo studies in inflammatory disease models, though such studies have not been reported in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Rhodojaponin V are not well established. Given its action on voltage-gated sodium channels, binding studies could involve radioligand displacement assays using membrane preparations from neuronal tissues or insect preparations. The compound's anti-inflammatory activity is typically assessed by measuring inhibition of LPS-induced nitric oxide production in RAW264.7 macrophages using the Griess assay.
|
| Cell Assay |
The in vitro cellular activity of Rhodojaponin V is evaluated in mouse RAW264.7 macrophage cells. Cells are stimulated with lipopolysaccharide (LPS) to induce nitric oxide (NO) production, and the compound's ability to inhibit NO production is measured using the Griess assay. The IC50 is determined from concentration-response curves. Cytotoxicity is typically assessed using MTT or similar assays to differentiate anti-inflammatory effects from general cytotoxicity.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for Rhodojaponin V. As a compound with insecticidal properties, it may be tested in insect models. For anti-inflammatory studies, potential in vivo models include carrageenan-induced paw edema or LPS-induced systemic inflammation in rodents, with administration routes depending on the specific experimental design.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for Rhodojaponin V. As a diterpenoid (molecular weight 410.50, formula C22H34O7), it is expected to have moderate lipophilicity. Standard storage conditions are 4degC, protected from light.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for Rhodojaponin V. As a natural product with neurotoxic and insecticidal properties, it may have significant toxicity. Standard laboratory safety precautions should be observed when handling this compound. No clinical toxicity studies have been reported.
|
| References | |
| Additional Infomation |
It has been reported that Japanese rhododendron (Rhododendron japonicum) contains 5,6,10,16-tetrahydroxy-2,3-epoxygrexin-14-ylacetate, and related data are available.
See also: Rhododendron V (note moved to). Rhodojaponin V is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity. It is not approved for clinical use and is intended for research purposes only. The compound is studied for its potential as a botanical pesticide and in neuropharmacological research. It is the C-14 acetylation product of Rhodojaponin III. |
| Molecular Formula |
C22H34O7
|
|---|---|
| Molecular Weight |
410.5012
|
| Exact Mass |
410.23
|
| CAS # |
37720-86-8
|
| PubChem CID |
169961
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
551.8±50.0 °C at 760 mmHg
|
| Melting Point |
232 °C
|
| Flash Point |
187.5±23.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.603
|
| LogP |
1.51
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
29
|
| Complexity |
768
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OHDPFRGZBUACTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H34O7/c1-10(23)28-16-11-6-7-12-20(5,26)15-14-17(29-14)18(2,3)22(15,27)13(24)8-21(12,16)9-19(11,4)25/h11-17,24-27H,6-9H2,1-5H3
|
| Chemical Name |
(3,4,10,15-tetrahydroxy-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.01,11.04,9.06,8]heptadecan-17-yl) acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~121.80 mM)
H2O : ~1 mg/mL (~2.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4361 mL | 12.1803 mL | 24.3605 mL | |
| 5 mM | 0.4872 mL | 2.4361 mL | 4.8721 mL | |
| 10 mM | 0.2436 mL | 1.2180 mL | 2.4361 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
